FY22 consensus $2.25B. Raises FY22 adjusted EBITDA view to $59M-$61M from $52M-$56M. Capital expenditures are expected to be less than $1M in full-year 2022. Adjusted EBITDA guidance includes new market start-up costs. 90%+ of Adjusted EBITDA expected to convert to free cash flow in FY 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRVA:
- Privia Health and Novant Health Enterprises Form Strategic Partnership
- Privia Health to Report Third Quarter 2022 Results on Thursday, November 10
- Director of Privia Health sold 80,853 shares of company stock
- Privia Health director sells $4.88M in common stock
- Privia Health management to meet with William Blair